Keywords: FDA, LABAs, Asthma, Labeling, GlaxoSmithKline, AstraZeneca, Novartis, Merck & Co, Advair, Serevent, Symbicort, Foradil

US FDA updates labeling on long-acting beta-agonists, notably GSK’s Advair and Serevent and AstraZeneca’s Symbicort

Article | 03 June 2010

Print This

The US Food and Drug Administration yesterday announced that long-acting beta-agonists (LABAs), used for the treatment of asthma and chronic ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in